JPS5988419A - Stable medicinal pharmaceutical - Google Patents
Stable medicinal pharmaceuticalInfo
- Publication number
- JPS5988419A JPS5988419A JP19958982A JP19958982A JPS5988419A JP S5988419 A JPS5988419 A JP S5988419A JP 19958982 A JP19958982 A JP 19958982A JP 19958982 A JP19958982 A JP 19958982A JP S5988419 A JPS5988419 A JP S5988419A
- Authority
- JP
- Japan
- Prior art keywords
- indomethacin
- stable medicinal
- observed
- medicinal pharmaceutical
- ointment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 29
- 229960000905 indomethacin Drugs 0.000 claims description 14
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003464 sulfur compounds Chemical class 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 239000002674 ointment Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 alkali metal bisulfite Chemical class 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 5
- 235000010262 sodium metabisulphite Nutrition 0.000 description 5
- 239000008213 purified water Substances 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- AOSFMYBATFLTAQ-UHFFFAOYSA-N 1-amino-3-(benzimidazol-1-yl)propan-2-ol Chemical compound C1=CC=C2N(CC(O)CN)C=NC2=C1 AOSFMYBATFLTAQ-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ARSLNKYOPNUFFY-UHFFFAOYSA-L barium sulfite Chemical compound [Ba+2].[O-]S([O-])=O ARSLNKYOPNUFFY-UHFFFAOYSA-L 0.000 description 1
- GBAOBIBJACZTNA-UHFFFAOYSA-L calcium sulfite Chemical compound [Ca+2].[O-]S([O-])=O GBAOBIBJACZTNA-UHFFFAOYSA-L 0.000 description 1
- 235000010261 calcium sulphite Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical class CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 229940099427 potassium bisulfite Drugs 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- RWPGFSMJFRPDDP-UHFFFAOYSA-L potassium metabisulfite Chemical compound [K+].[K+].[O-]S(=O)S([O-])(=O)=O RWPGFSMJFRPDDP-UHFFFAOYSA-L 0.000 description 1
- 235000010263 potassium metabisulphite Nutrition 0.000 description 1
- BHZRJJOHZFYXTO-UHFFFAOYSA-L potassium sulfite Chemical compound [K+].[K+].[O-]S([O-])=O BHZRJJOHZFYXTO-UHFFFAOYSA-L 0.000 description 1
- 235000019252 potassium sulphite Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
本発明は安定なインドメタシン外用剤に関する０
インドメタシンは、／−（ｐ −ｅｈｌｏｒｏｂｅｎｚ
０７１ ）−３； −ｍｅｔｈｏｘｙ −２−ｍｅｔｌ
ｙｌｉｎａｏｌｅ −３−ａｃｅｔｉｃ ａｃｉｄ（分
子式０１９Ｈ２６の０４ 、分子量ｓｗ、ｎ ）の化
学名を有する非ステロイド性消炎鎮痛剤であり、現在臨
床において広く使用されている。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a stable topical preparation of indomethacin.
071 )-3; -methoxy -2-metl
Ylinaole-3-acetic acid is a non-steroidal anti-inflammatory analgesic having the chemical name of ylinaole-3-acetic acid (molecular formula: 019H26, molecular weight: sw, n), and is currently widely used in clinical practice.
インドメタシンの従来からの投与方法である経口投与や
坐剤投与に心配される副作用を解消するために、局所に
直接投与６する外用剤としてすでに軟膏（特公昭５６−
／θざざ６）や外用液剤（特開昭！；６−３６グ／／）
がある。しかし、これらは基剤にインドメタシンを溶解
するものを用いるため、製造当初は黄色であるが、経時
的に着色し、褐色に変色するおそれがあった。In order to eliminate the side effects of the conventional administration methods of indomethacin, such as oral administration and suppository administration, an ointment (1983-1983) has already been developed as an external preparation for direct local administration6.
/θzaza6) and external liquid (Tokkai Sho!; 6-36g//)
There is. However, since these use a base that dissolves indomethacin, although the color is yellow at the time of manufacture, there is a risk that the color will change over time and turn brown.
そこで、本発明者らは、インドメタシン外用剤の着１色
防止方法について鋭意検討を重ねた結果、抗酸化剤とし
て知られる種々の安定化剤を添加したところ、はとんど
がその効力において不十分である中で、全く意外にもｌ
ＳＯ３−、ｓｏ３ 。Therefore, the inventors of the present invention have conducted intensive studies on methods for preventing color discoloration of topical preparations of indomethacin, and have added various stabilizers known as antioxidants, but most of them lack effectiveness. While enough, quite surprisingly l
SO3-, so3.
５２ｏ５２−イオンを生じさせる硫黄化合物から選ばれ
た７種又はそれ以上を添加することによって着色が防止
できることを見い出し、本発明を児成した。It has been discovered that coloring can be prevented by adding seven or more selected sulfur compounds that generate 52o52- ions, and the present invention has been completed.
硫黄化合物としては、例えば、亜硫酸水素塩（亜硫酸水
素ナトリウム、亜硫酸水素カリウム等の亜硫酸水素アル
カリ金属、亜硫酸水素アンモニウム）、亜硫酸塩（亜硫
酸ナトリウム、亜硫酸カリウム等の亜硫酸アルカリ金属
、亜硫酸カルシウム、亜硫酸バリウム等の亜硫酸アルカ
土類金属）、ピロ亜硫酸塩（ピロ亜硫酸ナトリラム、ピ
ロ亜硫酸カリウム等のどロ亜硫酸アルカリ金属）等があ
げられ、これらの安定化剤の添加量は安定化の効果と安
全性を考慮してθ、０／〜θ、Ｓ係がコ迄当である。Examples of sulfur compounds include bisulfites (alkali metal bisulfite such as sodium bisulfite and potassium bisulfite, ammonium bisulfite), sulfites (alkali metal sulfites such as sodium sulfite and potassium sulfite, calcium sulfite, barium sulfite, etc.) (alkaline earth metal sulfites), pyrosulfites (alkali metal sulfites such as sodium pyrosulfite, potassium pyrosulfite, etc.), and the amount of these stabilizers added should be determined based on the stabilizing effect and safety. The section θ, 0/~θ, S is in charge up to ko.
本発明の製剤は、軟膏剤、外用液剤などで、インドメタ
シンが雛解するような基剤を用いた外用剤であり、安定
化剤は水に溶解し、残りの基剤の中に混合して使用する
のが好ましい。The preparation of the present invention is an ointment, a liquid for external use, etc., which uses a base that dissolves indomethacin, and the stabilizer is dissolved in water and mixed into the remaining base. It is preferable to use
次に本発明の有用性について実験例で説明する０
実施例
インドメタシンを／ｙあたり／θ■含有するゲル軟膏に
オｉｌｉ々の安定化剤をθ、／チの濃度で添加する。こ
れらの軟を−を７θ２の軟膏チューブに充填した後、グ
θ℃、５６℃に保存したときの色の変化を観察した。Next, the usefulness of the present invention will be explained with experimental examples.Example A stabilizer such as oil is added to a gel ointment containing indomethacin per y/y at a concentration of θ,/h. These ointments were filled into ointment tubes at 7θ2 and then stored at 56°C and observed for color changes.
なお表中 −印は、変色が認められない０±印は、わ
ずかに変色が認めら
れる。In the table, the - mark indicates no discoloration, and the 0± mark indicates slight discoloration.
＋印は変色が認められる。+ mark indicates discoloration.
廿印は、顕著に変色が認められ ることを意味する。Significant discoloration is observed in the 廿 seal. It means to do something.
壕だ、この実験で使用したゲル軟膏の処方は、次のとお
りである。The formula for the gel ointment used in this experiment is as follows.
インドメタシン ７ｇプロピレング
リコール ／θ２モノラウリル酸ポリエチレ
ングリコール（／Ｃ１，Ｏ） ／ θ２アジピン
酸ジイソプロピル ２１エタノール
グθグジイソブ口パノールアミン
θ、３１カルボキシビニルポリマー ／１精
製 水 全量／θθ１ｄ２次に実施例
を示すが、本発明はこれらに限父されるものではない。Indomethacin 7g Propylene glycol / θ2 Polyethylene glycol monolaurate (/C1, O) / θ2 Diisopropyl adipate 21 Ethanol
Gujiisobutpanolamine
θ, 31 carboxyvinyl polymer /1 precision
Total amount of water produced/θθ1d2 Examples will be shown next, but the present invention is not limited to these.
実施例／ インドメタシン／２をクロタミトン３ｆｌ。Example/ Indomethacin/2 and crotamiton 3fl.
ポリエチレングリコールグθθＡ？、ペンジノアルコー
ル２ｇ、にアセチル化１＝糖変性７ノコール３Ｓ２に溶
解し、カルボキシビニル図■
リマー（ハイビスワコー７虞、 和光！薬＠’） ４係
水溶液ρｊ１を添加し、撹拌する。これしジイソプロパ
ツールアミンθ、Ｓ２、ピロ亜硫酸ナトリウムθ、／１
を精製水／θグに溶解（て加えたのち、さらに精製水を
加えて全量ンｉｏｏ ｙとし、全体が均一になるまで充
分にＰ拌し、インドメタシンゲル軟膏を得た。チューブ
に充填し、５６℃で３力月間保存したが、着色変化は見
られなかった。Polyethylene glycol θθA? , 2 g of pendinoalcohol, dissolved in acetylated 1 = sugar-modified 7 alcohol 3S2, carboxyvinyl diagram ■ rimer (Hibis Wako 7, Wako! Yaku@') 4 aqueous solution ρj1 was added and stirred. This diisopropanolamine θ, S2, sodium pyrosulfite θ, /1
After dissolving (adding) in purified water/θg, further purified water was added to make up the total volume, and the mixture was sufficiently stirred until the whole was homogeneous to obtain indomethacin gel ointment. Filled into a tube, Although it was stored at 56°C for 3 months, no color change was observed.
実施例！
実施例／のピロ亜硫酸ナトリウムの代りに亜硫酸ナトリ
ウムを用いて実施例と同様に調製し、インドメタシンゲ
ル軟膏を得た。チュに −ブに充填し、５０℃で３力
月間保存したが、着色変化は見られなかった。Example! Indomethacin gel ointment was prepared in the same manner as in Example except that sodium sulfite was used in place of sodium pyrosulfite in Example. The mixture was filled into tubes and stored at 50°C for 3 months, but no color change was observed.
実施例３
実施例／のピロ亜硫酸ナトリウムの代りにし 亜硫酸
水素ナトリウムを用いて実施例／と同し 様に調製し
、インドメタシンゲル軟膏を得た。Example 3 Indomethacin gel ointment was prepared in the same manner as in Example, except that sodium bisulfite was used instead of sodium pyrosulfite in Example.
チューブに充填し、５θ°Ｃで３カ月間保存しど
たが着色変化は見られなかった。Fill a tube and store at 5θ°C for 3 months.
However, no color change was observed.
＝ 実施例な
狂 インドメタシン／１をモノラウリン酸ポリエチ
レングリコール（／θに、Ｏ，）／θ１、ア、 ジ
ピン酸ジイソプロピル、５ノ、イソプロピル〃 アル
コール＋２０１、エチルアルコール３０２に、溶解する
。これにジイソプ口バノールアミンθ、、２５１’ 、
ピロ亜硫酸ナトリウム０．７１を精製水１０ｆに溶解し
て加えたのち、さらに精製水を加えて全量を／θθｄと
し、インドメタシン列用液剤を得た。プラスチック容器
に充填し、５６℃で３カ月間保存しだが着色変化は見ら
れなかった。= Examples Indomethacin/1 is dissolved in polyethylene glycol monolaurate (/θ, O,)/θ1, diisopropyl dipate, 5, isopropyl alcohol +201, and ethyl alcohol 302. In addition to this, diisobanolamine θ, 251',
After adding 0.71 g of sodium pyrosulfite dissolved in 10 f of purified water, further purified water was added to make the total amount /θθd to obtain a liquid preparation for indomethacin series. It was filled into a plastic container and stored at 56°C for 3 months, but no color change was observed.
Claims (1)
３ 。 ５２０５２−から選ばれたイオンの少なくとも一種を生
ずる硫黄化合物を一種あるいは二種以上を含むととを特
徴とするインドメタシン外用剤０[Claims] 1) Indomethacin and ii) H3O3-, S0
3. Indomethacin topical preparation 0, characterized in that it contains one or more sulfur compounds that produce at least one ion selected from 52052-
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19958982A JPS5988419A (en) | 1982-11-12 | 1982-11-12 | Stable medicinal pharmaceutical |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP19958982A JPS5988419A (en) | 1982-11-12 | 1982-11-12 | Stable medicinal pharmaceutical |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5988419A true JPS5988419A (en) | 1984-05-22 |
| JPH049770B2 JPH049770B2 (en) | 1992-02-21 |
Family
ID=16410355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP19958982A Granted JPS5988419A (en) | 1982-11-12 | 1982-11-12 | Stable medicinal pharmaceutical |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5988419A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991012821A1 (en) * | 1990-03-02 | 1991-09-05 | Shiseido Company, Ltd. | Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic |
| JP2002128701A (en) * | 2000-10-26 | 2002-05-09 | Sankyo Co Ltd | External antiphologistic and analgesic agent composition |
| JP2002145775A (en) * | 2000-11-02 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | Stable external solution |
| WO2007046318A1 (en) * | 2005-10-17 | 2007-04-26 | Kowa Co., Ltd. | Liquid preparation for external application containing indomethacin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5134444A (en) * | 1974-07-26 | 1976-03-24 | Gea Kuehlturmbau & Systemtech | |
| JPS5636411A (en) * | 1979-08-31 | 1981-04-09 | Sumitomo Chem Co Ltd | Liquid agent for external use |
| JPS5798209A (en) * | 1980-12-09 | 1982-06-18 | Kowa Co | Remedy for dermatopathy for external use |
| JPS57128623A (en) * | 1981-02-03 | 1982-08-10 | Kowa Co | External solution of indomethacin |
-
1982
- 1982-11-12 JP JP19958982A patent/JPS5988419A/en active Granted
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5134444A (en) * | 1974-07-26 | 1976-03-24 | Gea Kuehlturmbau & Systemtech | |
| JPS5636411A (en) * | 1979-08-31 | 1981-04-09 | Sumitomo Chem Co Ltd | Liquid agent for external use |
| JPS5798209A (en) * | 1980-12-09 | 1982-06-18 | Kowa Co | Remedy for dermatopathy for external use |
| JPS57128623A (en) * | 1981-02-03 | 1982-08-10 | Kowa Co | External solution of indomethacin |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991012821A1 (en) * | 1990-03-02 | 1991-09-05 | Shiseido Company, Ltd. | Oil-in-water emulsion composition containing nonsteroidal antiphlogistic analgesic |
| US5256691A (en) * | 1990-03-02 | 1993-10-26 | Shiseido Company Ltd. | Oil-in-water type emulsified composition comprising non-steroidal antiphlogistic and analgesic drug |
| JP3340126B2 (en) * | 1990-03-02 | 2002-11-05 | 株式会社資生堂 | Oil-in-water emulsion composition containing non-steroidal anti-inflammatory drug |
| JP2002128701A (en) * | 2000-10-26 | 2002-05-09 | Sankyo Co Ltd | External antiphologistic and analgesic agent composition |
| JP2002145775A (en) * | 2000-11-02 | 2002-05-22 | Sumitomo Pharmaceut Co Ltd | Stable external solution |
| WO2007046318A1 (en) * | 2005-10-17 | 2007-04-26 | Kowa Co., Ltd. | Liquid preparation for external application containing indomethacin |
| US8673960B2 (en) | 2005-10-17 | 2014-03-18 | Kowa Co., Ltd. | External liquid preparation containing indomethacin |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH049770B2 (en) | 1992-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2085191C1 (en) | Liquid antibacterial composition | |
| JPS63132833A (en) | Stable injection containing 3-methyl-1-phenyl-2-pyrazolon-5-one | |
| JPH03232816A (en) | Syrup composition | |
| JP4302990B2 (en) | Injection containing a stable and high concentration pyrazolone derivative | |
| JPH11514013A (en) | A novel stable liquid formulation of paracetamol and its production method | |
| JPH03849B2 (en) | ||
| RU2062616C1 (en) | Liquid medicinal form of piroxicam | |
| KR960003327B1 (en) | Salts of diclofenac with cyclic organic bases and pharmaceutical compositions containing them | |
| JPS5988419A (en) | Stable medicinal pharmaceutical | |
| PT89144B (en) | PROCESS FOR THE PREPARATION OF AN INJECTABLE SOLUTION OF THIOCHARID ACID SALT WITH TROMETAMOL AND / OR BASIC AMINO ACIDS | |
| US3002886A (en) | Betaine salicylates and the method for their preparation | |
| CA2270004C (en) | Stable mitoxantrone solutions | |
| US4582845A (en) | Pharmaceutical composition for injection | |
| JPS6393718A (en) | Injection | |
| HU179989B (en) | Process for preparing pharmacological compositions containing r-/+/-1-/1-phenyl-ethyl/-1h-imidazol-5-carboxylic acid ethyl ester for intravenous administration | |
| KR890000905B1 (en) | Formulation parenteral | |
| JPH0132805B2 (en) | ||
| SU1090404A1 (en) | Method of preparing sibasone solution for injections | |
| US2464284A (en) | Vasoconstrictor composition | |
| NL8203280A (en) | N-METHYL-D-GLUCAMINE SALT; SOLUTION THEREOF. | |
| JP4782917B2 (en) | Stable external liquid | |
| EP0055593A2 (en) | Compositions comprising E-prostaglandins | |
| US2196495A (en) | Isopropanolamine salts of theophylline and process of making them | |
| ES2129023T3 (en) | DERIVATIVES OF BENZO (C) FENANTRIDINIO. | |
| SU1268170A1 (en) | Antirheumatoid agent "pyrimidant" |